Novartis pharma sales down in 4Q, but Alcon and Sandoz units see profits
This article was originally published in Scrip
Executive Summary
Novartis's pharmaceutical sales struggled in the fourth quarter of 2014 because of increased generic competition, but its own generics division Sandoz and ophthalmology unit Alcon both saw increases in the quarter.